Equities

Enzolytics Inc

ENZC:PKC

Enzolytics Inc

Actions
  • Price (USD)0.002
  • Today's Change0.000 / 3.63%
  • Shares traded886.44k
  • 1 Year change-95.65%
  • Beta1.0679
Data delayed at least 15 minutes, as of Jul 03 2024 17:56 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Enzolytics, Inc. is a drug development company. The Company is engaged in the commercialization of its proteins and monoclonal antibodies for the treatment of debilitating infectious diseases. Its patented and clinically tested compound, ITV-1 (Immune Therapeutic Vaccine-1), is a suspension of Inactivated Pepsin Fraction (IPF) for the treatment of human immunodeficiency virus/ acquired immunodeficiency syndrome (HIV/AIDS). It has a technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases which is being employed to produce monoclonal antibody therapeutics for treating the Coronavirus (SARS-CoV-2), HIV-1 and the Feline Leukemia virus. The Company also plans to produce mAbs targeting many other viruses, including HIV-2, Influenza A and B, H1N1 influenza, Respiratory syncytial virus (RSV), Small-Pox, Ebola Virus, Tetanus, Diphtheria, HTLV-1/2, Rabies, Herpes zoster, Varicella zoster, Anthrax, Mason-Pfizer monkey virus (MPMV) and Visna virus (VISNA).

  • Revenue in USD (TTM)0.00
  • Net income in USD-119.19k
  • Incorporated2020
  • Employees2.00
  • Location
    Enzolytics Inc120 W Pomona AveMONROVIA 91016United StatesUSA
  • Phone+1 (626) 538-4779
  • Fax+1 (845) 818-3588
  • Websitehttps://enzolytics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
HST Global Inc0.00-141.11k5.72m1.00---------0.0269-0.02690.00-0.11930.00-------29,397.92-5,836.01---------------24.24---------0.7858------
Intelligent Bio Solutions Inc2.83m-10.03m5.74m17.00--0.4816--2.03-64.14-64.144.603.820.20412.697.77166,299.40-72.67-80.65-107.67-224.8423.33---356.09-948.541.87--0.0451--187.51367.97-28.00------
Transcode Therapeutics Inc0.00-17.06m5.75m10.00--1.10-----206.36-206.360.000.78930.00----0.00-264.82-133.14-721.90-181.26-----------148.050.00-------5.59------
Xenetic Biosciences Inc2.44m-4.47m5.77m4.00--0.6648--2.36-2.92-2.921.595.630.2116----611,240.00-38.71-48.91-41.54-52.82-----182.95-682.42----0.00--48.80--36.90------
CeCors Inc-100.00bn-100.00bn5.81m6.00---------------0.0163------------------------------------22.70------
Burzynski Research Institute Inc0.00-1.34m5.83m2.00---------0.0102-0.01020.00-0.00020.00-------62,992.45-15,304.89-------------------------45.74------
NuCana PLC (ADR)0.00-33.89m5.84m25.00--0.4868-----302.91-302.910.005.670.00----0.00-72.34-41.01-125.17-48.07------------0.0324------13.71---21.70--
Ainos Inc93.68k-14.56m5.91m46.00--0.2547--63.06-3.27-3.270.02063.690.00280.81331.622,036.52-43.83-36.36-48.64-58.33-222.1136.82-15,547.49-813.630.2847-75.230.2003---96.539.461.69--66.44--
Cyclerion Therapeutics Inc0.00-10.95m6.11m1.00--0.568-----4.380.29040.003.970.00----0.00-95.95-72.70-158.12-86.96-------2,565.62----0.00---100.00--30.98------
Tenax Therapeutics Inc0.00-10.10m6.23m5.00--0.501-----24.52-24.520.006.350.00----0.00-67.96-199.16-75.66-285.64-----------105.120.0322------30.21------
Kazia Therapeutics Ltd (ADR)15.12k-13.72m6.27m12.00--0.5936--414.27-0.8322-0.83220.00080.35430.0007--73.97---63.98-46.35-82.39-54.75-----90,714.45-497.17----0.1297--979.43-28.3118.19------
Enzolytics Inc0.00-119.19k6.38m2.00---------0.106-0.1060.00-1.040.00-------369.52-----------------4.30-----100.00---9.35------
ENDRA Life Sciences Inc0.00-9.89m6.39m21.00--0.2686-----1.26-1.260.000.33880.00----0.00-168.89-132.00-228.29-157.28------------0.00------23.67---19.46--
Virios Therapeutics Inc0.00-5.07m6.66m4.00---------0.2673-0.26730.00--------------------------------------56.76------
Kineta Inc5.16m-17.89m6.88m11.00------1.33-1.55-1.550.4673-0.5640.6667----469,181.80-230.51-66.16---86.61-----345.77-854.74--------178.6513.8977.76------
Viaderma Inc17.80m2.31m6.91m75.000.00030.000021.280.388116.8416.84129.62255.590.412624.691.21237,331.305.36--6.53--28.90--12.99--2.075.660.1718---29.15---40.70------
Data as of Jul 03 2024. Currency figures normalised to Enzolytics Inc's reporting currency: US Dollar USD

Institutional shareholders

0.06%Per cent of shares held by top holders
HolderShares% Held
Hilltop Partners LLCas of 31 Mar 20241.95m0.06%
HighPoint Advisor Group LLCas of 31 Mar 202438.47k0.00%
Vermillion & White Wealth Management Group LLCas of 31 Mar 202429.86k0.00%
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.